Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus paclitaxel in EGFR+ gastric cancer
NCT02501603Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jul 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Yonsei University. Primary endpoint: Progression-Free Survival. Started Jul 2016; status: completed.
02
Drugs
afatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02501603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501603.